Showing 1 - 3 results of 3 for search 'Joseph H. Lubin' Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Author
  • Joseph H. Lubin
Showing 1 - 3 results of 3 for search 'Joseph H. Lubin', query time: 0.04s Refine Results
  1. 1
    Modeling of ACE2 and antibodies bound to SARS-CoV-2 provides insights into infectivity and immune evasion

    Modeling of ACE2 and antibodies bound to SARS-CoV-2 provides insights into infectivity and immune evasion by Joseph H. Lubin, Christopher Markosian, D. Balamurugan, Minh T. Ma, Chih-Hsiung Chen, Dongfang Liu, Renata Pasqualini, Wadih Arap, Stephen K. Burley, Sagar D. Khare

    Published 2023-07-01
    Get full text
    Article
  2. 2
    Corrigendum to “Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus” [Heliyon 9(4) (April 2023) e15032]

    Corrigendum to “Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntib... by Nancy E. Hernandez, Wojciech Jankowski, Rahel Frick, Simon P. Kelow, Joseph H. Lubin, Vijaya Simhadri, Jared Adolf-Bryfogle, Sagar D. Khare, Roland L. Dunbrack, Jr., Jeffrey J. Gray, Zuben E. Sauna

    Published 2023-08-01
    Get full text
    Article
  3. 3
    Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus

    Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD)... by Nancy E. Hernandez, Wojciech Jankowski, Rahel Frick, Simon P. Kelow, Joseph H. Lubin, Vijaya Simhadri, Jared Adolf-Bryfogle, Sagar D. Khare, Roland L. Dunbrack, Jr., Jeffrey J. Gray, Zuben E. Sauna

    Published 2023-04-01
    Get full text
    Article

Search Tools:

  • RSS Feed
  • Email Search

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs